These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16221106)

  • 1. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
    Seng WK; Hwang SJ; Han DC; Teong CC; Chan J; Burke TA; Carides GW; Choi YJ
    Nephrology (Carlton); 2005 Oct; 10(5):520-4. PubMed ID: 16221106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH; Shahinfar S; Carides GW; Dasbach EJ; Gerth WC; Alexander CM; Cook JR; Keane WF; Brenner BM
    Diabetes Care; 2003 Mar; 26(3):683-7. PubMed ID: 12610022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
    Szucs TD; Sandoz MS; Keusch GW
    Swiss Med Wkly; 2004 Aug; 134(31-32):440-7. PubMed ID: 15389347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
    Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
    Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
    Carides GW; Shahinfar S; Dasbach EJ; Keane WF; Gerth WC; Alexander CM; Herman WH; Brenner BM;
    Pharmacoeconomics; 2006; 24(6):549-58. PubMed ID: 16761903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
    Alexander CM; Lyle PA; Keane WF; Carides GW; Zhang Z; Shahinfar S
    Kidney Int Suppl; 2004 Nov; (92):S115-7. PubMed ID: 15485403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S; Citarella A; Cammarota S; Menditto E; Mantovani LG
    Clin Exp Hypertens; 2011; 33(3):174-8. PubMed ID: 21466388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
    Stafylas PC; Sarafidis PA; Lasaridis AN; Tsakni E; Niakas DA; Dombros NV; Grekas DM; Bakris GL
    J Nephrol; 2007; 20(6):703-15. PubMed ID: 18046673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
    Souchet T; Durand Zaleski I; Hannedouche T; Rodier M; Gaugris S; Passa P;
    Diabetes Metab; 2003 Feb; 29(1):29-35. PubMed ID: 12629445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
    González F F; Fuentes C V; Castro H C; Santelices L JP; Lorca H E
    Rev Med Chil; 2009 May; 137(5):634-40. PubMed ID: 19701552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
    Chan JC; Wat NM; So WY; Lam KS; Chua CT; Wong KS; Morad Z; Dickson TZ; Hille D; Zhang Z; Cooper ME; Shahinfar S; Brenner BM; Kurokawa K;
    Diabetes Care; 2004 Apr; 27(4):874-9. PubMed ID: 15047641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom.
    Vora J; Carides G; Robinson P
    Curr Ther Res Clin Exp; 2005 Nov; 66(6):475-85. PubMed ID: 24678070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
    Shahinfar S; Dickson TZ; Ahmed T; Zhang Z; Ramjit D; Smith RD; Brenner BM;
    Kidney Int Suppl; 2002 Dec; (82):S64-7. PubMed ID: 12410858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B; Gleim G; Panish J
    Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.